Desogestrel, etonogestrel and meningioma risk: how frequent does an adverse effect have to be worth mentioning?

Q: What does this research mean for the field?

Determining the frequency threshold for reporting adverse effects, such as the potential meningioma risk with desogestrel and etonogestrel, is a critical challenge in pharmacovigilance and regulatory communication. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Giovanni Grandi; Carlo Bastianelli; Manuela Farris

doi:10.1080/13625187.2026.2718925

August 20, 2026The European Journal of Contraception & Reproductive Health Care

Desogestrel, etonogestrel and meningioma risk: how frequent does an adverse effect have to be worth mentioning?

View at Publisher

Ask AI

Bookmark

Share

Key Points

Assess the risk of meningioma associated with desogestrel and etonogestrel use and examine regulatory thresholds for issuing safety communications.
Evaluation of regulatory safety data and pharmacovigilance assessments from the European Medicines Agency's Pharmacovigilance Risk Assessment Committee.
Regulatory assessments examined the incidence of meningioma to determine if direct safety alerts to healthcare professionals are warranted.
The evaluation emphasizes the critical frequency threshold required before rare progestogen-associated adverse effects necessitate formal clinical warnings.

Implication

Safety review analyzes meningioma risk linked to desogestrel and etonogestrel, highlighting clinical thresholds for pharmacovigilance warnings.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Grandi et al. (2026) studied this question.

synapsesocial.com/papers/6a895fc4ca7ade938187e980 https://doi.org/10.1080/13625187.2026.2718925

View at Publisher

Ask AI

Bookmark

Share

Desogestrel, etonogestrel and meningioma risk: how frequent does an adverse effect have to be worth mentioning?

Key Points

Implication

Abstract

Discussion

Cite This Study

Desogestrel, etonogestrel and meningioma risk: how frequent does an adverse effect have to be worth mentioning?

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from The European Journal of Contraception & Reproductive Health Care

Keep reading

More related papers

More from The European Journal of Contraception & Reproductive Health Care